The fluoroquinolones as a class of antibacterial agents first experienced widespread clinical use during the 1980s with the release of norfloxacin and ciprofloxacin (13) . Since then, numerous additional fluoroquinolones have been developed. In general, the fluoroquinolones have proven to be effective in the management of infections due to gram-negative bacteria (1, 25) . The utility of currently available agents in treating infections caused by gram-positive organisms is questionable (21) . Streptococcus pneumoniae is of particular concern, as evidenced by reports of incomplete bacterial eradication and therapeutic failure with ciprofloxacin (5, 16, 17, 20) . As penicillin resistance has emerged as a major problem with S. pneumoniae (2) , effective, alternative non-␤-lactam therapies have become necessary. In this regard, the recent development of several fluoroquinolones with extended gram-positive activity is of interest (21) .
This study was undertaken to assess the in vitro activity of a novel 8-methoxyquinolone, BAY 12-8039 (1-cyclopropyl-7[(S,S)-2,8-diazabicyclo[4.3.0] non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid) against S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Preliminary reports describing the in vitro activity of BAY 12-8039 indicate that this new agent possesses the typical activity profile of a fluoroquinolone against gram-negative bacteria such as the Enterobacteriaceae and Pseudomonas, Chlamydia, and Mycoplasma species, in addition to having an added spectrum of gram-positive activity (10, 12, 15, 23, 24, 26) . In this study, we compared the in vitro activity of BAY 12-8039 to those obtained with six other quinolones, ciprofloxacin, ofloxa-cin, levofloxacin, sparfloxacin, trovafloxacin, and clinafloxacin, against S. pneumoniae. The latter four agents were chosen because of their extended gram-positive activity (3, 4, 9) . Because of the frequency with which S. pneumoniae is recognized as a cause of outpatient infections that are typically treated empirically, i.e., acute otitis media, maxillary sinusitis, acute purulent exacerbation of chronic bronchitis, and communityacquired pneumonia, we also assessed the activities of the fluoroquinolones against recent clinical isolates of two other bacteria that commonly cause these diseases, H. influenzae and M. catarrhalis.
MATERIALS AND METHODS
Representative isolates of S. pneumoniae (n ϭ 404), H. influenzae (n ϭ 330), and M. catarrhalis (n ϭ 250) were selected from a collection of clinical isolates obtained from outpatients in 30 United States medical centers during the winter months of 1994 to 1995 as part of a national surveillance study of antimicrobial resistance (6) (7) (8) . Broth microdilution as recommended by the National Committee for Clinical Laboratory Standards (18) was used to determine MICs. The following media were used: S. pneumoniae, cation-adjusted Mueller-Hinton broth (MHB) supplemented with 3% lysed horse blood; H. influenzae, haemophilus test medium (14) ; and M. catarrhalis, MHB. The following American Type Culture Collection control strains were used: S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, ATCC 10211, and ATCC 49766, and Escherichia coli ATCC 25922. Antimicrobials were obtained as laboratory grade powders from their respective manufacturers: BAY 12-8039, Bayer Corporation; ciprofloxacin, Miles Pharmaceuticals; clinafloxacin, Parke-Davis Pharmaceutical; levofloxacin and ofloxacin, Roussel Uclaf; sparfloxacin, Rhone-Poulenc Rorer; and trovafloxacin, Pfizer, Inc. Isolates were stored at Ϫ70°C by using porous beads with two subcultures made before the organisms were tested. Following inoculation (ca. 5 ϫ 10 5 CFU/ml final inoculum concentration), MIC trays were incubated at 37°C in ambient air for 24 h before examination. Table 1 . BAY 12-8039 and clinafloxacin, both with a MIC at which 90% of the isolates were inhibited (MIC 90 ) of 0.06 g/ml, had the highest levels of activity against S. pneumoniae compared to the other compounds. These values were twofold lower than the MIC 90 s obtained with sparfloxacin and trovafloxacin and eightfold lower than those obtained with levofloxacin, ofloxacin, or ciprofloxacin. There was no difference in the overall activity of any of the seven agents examined in this study against penicillin-susceptible, -intermediate, or -resistant S. pneumoniae. MIC 50 s and MIC 90 s were nearly identical for individual antimicrobials, regardless of penicillin susceptibility category. The rank order of activity among this group of fluoroquinolones versus S. pneumoniae was as follows: BAY 12-8039 ϭ clinafloxacin Ͼ trovafloxacin ϭ sparfloxacin Ͼ levofloxacin Ͼ ciprofloxacin ϭ ofloxacin.
RESULTS

Results of MIC determinations are listed in
Two strains of S. pneumoniae for which the MICs were conspicuously higher than the range of MICs noted for the general population were detected. The BAY 12-8039, clinafloxacin, trovafloxacin, sparfloxacin, levofloxacin, ciprofloxacin, and ofloxacin MICs for one strain were 1, 0.25, 1, 2, 4, Ͼ8, and 8 g/ml, respectively. For the other strain, the respective MICs were 4, 0.5, 8, 16, 16, Ͼ8, and Ͼ16 g/ml. Excluding these two strains, the range of MICs obtained with the seven agents examined in this study versus all isolates of S. pneumoniae were as follows: BAY 12-8039, Յ0.004 to 0.06 g/ml; clinafloxacin, 0.015 to 0.12 g/ml; trovafloxacin, Յ0.004 to 0.25 g/ml; sparfloxacin, 0.06-0.25 g/ml; levofloxacin, 0.25 to 1 g/ml; ciprofloxacin, 0.25 to 2 g/ml; and ofloxacin, 0.5 to 2 g/ml. It is possible that the two strains of S. pneumoniae for which the fluoroquinolone MICs were uniformly higher represent resistant organisms. Both of these isolates have proven to be far more refractory to treatment with fluoroquinolones than susceptible strains in a neutropenic murine model of pneumococcal lung infection (data not shown).
The effects of the MIC test format and the incubation atmosphere on BAY 12-8039 MICs versus S. pneumoniae were investigated by simultaneously determining the BAY 12-8039 MICs for selected strains by agar dilution and broth microdilution with plates and trays incubated in both CO 2 and ambient air. For the purpose of comparison, ciprofloxacin was also tested in this manner. As can be seen in Table 2 , CO 2 incubation led to a marked increase in the MICs of BAY 12-8039 in both test formats. In addition, when the incubation atmosphere was kept constant, MICs determined by agar dilution were consistently lower than MICs determined by broth microdilution. The effects of incubation atmosphere and test format on ciprofloxacin MICs were not as pronounced.
In an attempt to understand the CO 2 effect the pHs of Mueller-Hinton agar supplemented with 5% defibrinated sheep blood (the medium used for agar dilution tests) and MHB plus 5% lysed horse blood (the medium used for broth microdilution MIC determinations) were determined before and after 24-h incubations (with and without antibiotics) in both 5 to 7% CO 2 and ambient air. The initial pH of Mueller-Hinton sheep blood agar was 7.43 to 7.45; after incubation of plates for 24 h in air, the pH range was 7.38 to 7.40; after incubation for the same period in 5 to 7% CO 2 , the pH dropped to 6.97 to 6.98. The same pattern was observed with Mueller-Hinton lysed horse blood broth: initial pH, 7.56 to 7.57; pH after 24-h incubation in air, 7.60 to 7.62; pH after 24-h incubation in 5 to 7% CO 2 , 6.96 to 6.98.
All seven quinolones displayed high levels of activity against H. influenzae and M. catarrhalis ( Table 1 ). The MIC 90 s ranged from 0.008 to 0.06 g/ml for H. influenzae and from 0.008 to 0.12 g/ml for M. catarrhalis. However, as was the case with two isolates of S. pneumoniae, one strain of H. influenzae seemed to distinguish itself as perhaps being fluoroquinolone resistant; for this strain, the MIC of clinafloxacin was 2 g/ml and that of the remaining antibiotics was Ͼ2 g/ml.
DISCUSSION
We are unaware of previous published work describing the in vitro activity of BAY 12-8039 versus large numbers of recent clinical isolates of S. pneumoniae, H. influenzae, and M. catarrhalis. A single published study described the activity of BAY 12-8039 versus small numbers of strains (i.e., 30 to 36) of S. pneumoniae, H. influenzae, and M. catarrhalis taken from a noncontemporary stock culture collection (26) . In addition, one abstract at the 1996 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) addressed the in vitro activity of BAY 12-8039 versus all three of these organ-isms (12) . Four others described the activity of BAY 12-8039 versus only S. pneumoniae (10, 15, 23, 24) . In general, our findings concerning the in vitro activity of BAY 12-8039 versus H. influenzae and M. catarrhalis are consistent with the observations of previous reports (12, 26) . In addition, the absolute and relative in vitro activities of the six other fluoroquinolones examined in this study versus S. pneumoniae, H. influenzae, and M. catarrhalis are consistent with the observations of several previously published investigations (3, 4, 9, 21) .
Our observations regarding the in vitro activity of BAY 12-8039 versus S. pneumoniae, however, differed from those published (26) as well as from those described at the 1996 ICAAC meeting (10, 12, 15, 23, 24) . Specifically, the MIC 50 s and MIC 90 s we obtained (i.e., 0.03 and 0.06 g/ml, respectively) were consistently two-to fourfold lower than those previously reported. In an attempt to explain these differences, several study strains were tested simultaneously by agar dilution in CO 2 , the method used by previous investigators, and by broth microdilution with trays incubated in ambient air, as was done in the current investigation. Consistently, two-to fourfold-lower MICs were obtained by the latter method. Further experimentation suggested that the noted differences might be due to the effects of CO 2 incubation of agar dilution plates. CO 2 incubation clearly produced a marked pH decrease in test media, perhaps directly diminishing the activity of BAY 12-8039, or perhaps altering the growth characteristics of test strains, in turn leading to a decrease in the expression of BAY 12-8039 activity. In either case, CO 2 incubation of both agar dilution plates and broth microdilution trays resulted in elevated MICs. In addition to this CO 2 effect, it was observed that BAY 12-8039 MICs were consistently higher in the agar dilution format than in the broth microdilution test. Inasmuch as current National Committee for Clinical Laboratory Standards recommendations for quantitative susceptibility testing of S. pneumoniae advocate the use of broth microdilution trays incubated in ambient air (18) , we assert that the generally lower MICs obtained with BAY 12-8039 versus S. pneumoniae in the current study should be considered valid. In view of these observations and assuming acceptable pharmacokinetic and toxicity profiles, clinical trials of BAY 12-8039 for the management of infections caused by the three organisms noted above appear to be warranted.
The results of the current study are also notable for the recognition of two clinical isolates of S. pneumoniae and one of H. influenzae that appeared to be quinolone resistant. Such strains have been described previously but infrequently (11, 19, 20) . Stepwise selection of quinolone resistance in the laboratory has been clearly demonstrated with S. pneumoniae (19, 22) . This, however, has not been demonstrable with H. influenzae. Selection of ciprofloxacin-resistant strains of S. pneumoniae has also been observed in patients receiving this agent (19, 20) . Quinolone resistance for S. pneumoniae has been shown in both laboratory-selected strains and clinical isolates to be the result of primary mutations in the ParC subunit of topoisomerase IV and secondary mutations in the GyrA subunit of DNA gyrase (19) . The molecular basis for quinolone resistance in H. influenzae has not yet been elucidated. An attempt to define the mutations responsible for the diminished quinolone activity seen in two pneumococcal isolates and in one strain of H. influenzae characterized in this study is in progress.
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